PHRPhreesia, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−6% a year). The price demands less than its three-year revenue growth of 17% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PHR's price assumes
Phreesia, Inc. trades at 62.7× earnings against 45.1× for the median Health Information Services name, more expensive than its own group.
Trailing P/E · Health Information Services median 45.1 · 1.39× the median: the market pays up for this one
- Free cash flow yield
- 12%
Free cash flow yield · Health Information Services median 6.3%
- Growth the price implies
- −6.5%
Growth the price implies · The price pays for −6.5% free cash flow growth a year for a decade; revenue has grown +17% a year over the last three.
Details›
- EV / EBIToperating margin 2.5%: the multiple describes the denominator
- not meaningful
- Healthcare median P/E509 names
- 26.0
- Health Information Services median P/E25 names
- 45.1
- Free cash flow, trailing twelve months
- $81M
- Market capitalisation
- $659M
- 3-year revenue growth
- +17%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #10 of 20 by RyuScore